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Abstract
VonWillebrand disease (VWD) may be caused by an impaired von Willebrand factor (VWF)
synthesis, its increased clearance or abnormal function, or combinations of these factors. It
may be difficult to recognize the different contributions of these anomalies. Here we demon-
strate that VWD diagnostics gains from measuring platelet VWF, which can reveal a defec-
tive VWF synthesis. Measuring platelet VWF revealed that: severe type 1 VWD always
coincided with significantly lower platelet and plasma VWF levels, whereas mild forms
revealed low plasma VWF levels associated with low or normal platelet VWF levels, and the
latter were associated with a slightly shorter VWF survival; type Vicenza (the archetype
VWD caused by a reduced VWF survival) featured normal platelet VWF levels despite sig-
nificantly reduced plasma VWF levels; type 2B patients could have either normal platelet
VWF levels associated with abnormal multimer patterns, or reduced platelet VWF levels
associated with normal multimer patterns; type 2A patients could have reduced or normal
platelet VWF levels, the former associated mainly with type 2A-I, the latter with type 2A-II;
plasma and platelet VWF levels were normal in type 2N, except when the defect was asso-
ciated with a quantitative VWFmutation. Our findings show that measuring platelet VWF
helps to characterize VWD, especially the ambiguous phenotypes, shedding light on the
mechanisms underlying the disorder.
Introduction
VonWillebrand factor (VWF) is a high-molecular-weight multimeric glycoprotein with a fun-
damental role in the early stages of hemostasis, promoting the binding of platelet VWF at the
site of vascular injury [1]. It also serves as a carrier of FVIII [2]. VWF is found in plasma, plate-
lets, megakaryocytes, endothelial cells and the subendothelial matrix, and it is synthesized by
endothelial cells and megakaryocytes [3,4]. VWF synthesized in endothelial cells is either
stored in Weibel Palade bodies or constitutively secreted into the plasma, which assures circu-
lating VWF levels [4,5]. Platelet VWF synthesized by megakaryocytes accounts for 10% to 20%
of all the VWF in the blood. It is secreted from the alpha granules at the site of vascular injury
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following platelet activation and during platelet plug formation [6]. Both plasma and platelet
VWF are therefore involved in primary hemostasis.
Although definitive proof is still lacking, it is currently accepted that VWF is biosynthesized
in megakaryocytes and endothelial cells in much the same way, but a number of important
differences have emerged between platelet and plasma VWF. First of all, platelet VWF is richer
in hemostatically active ultra-large VWFmultimers [6], and it reveals no triplet pattern on
multimer analysis [7], confirming the recent claim that platelet VWF is more resistant to
ADAMTS13 proteolysis than plasma VWF [8]. The sialylation of N-linked glycans is also at
least 50% lower for platelet VWF than for plasma VWF [7–9], and while there are O blood
group structures on platelet VWF, there are no group A- or B-glycans [10,11]. ABO blood
group consequently influences circulating VWF concentrations, but has no effect on platelet
VWF levels [12,13].
VWF quantitative reductions and/or abnormalities lead to vonWillebrand disease (VWD),
which is probably the most common inherited bleeding disorder. Quantitative VWF defects
cause VWD type 1 and type 3, while VWF functional abnormalities are responsible for type 2,
which involves a defective interaction with platelets (types 2A, 2B and 2M) or FVIII (type 2N)
[14]. The heterogeneity of the VWD phenotype also concerns platelet VWF content, which dif-
fers in the various types and subtypes of the disease [15,16]. Studies conducted in the past on
type 1 VWD with both low and normal platelet VWF content demonstrated that the latter
form is characterized by shorter bleeding times than the former [17]. This difference was used
to distinguish type 1 VWD patients from those with other variants of the disease [17]. In type 3
VWD patients, on the other hand, combined infusions of cryoprecipitate and platelets can cor-
rect or considerably improve bleeding times, whereas cryoprecipitate infusion alone cannot
[18]. The above findings are confirmed by the observation that pigs with severe VWD
engrafted with normal bone marrow produce platelets with a normal VWF, and bleeding times
become shorter than before the transplant, despite unchanged plasma VWF levels [19]. Other
studies in pigs showed less conclusive results, however, and indicated that plasma VWF is the
major determinant of bleeding time [20]. Taken together, these findings show that platelet
VWF contributes to hemostasis, and that its role may vary within the heterogeneous setting of
VWD.
Here we report on the platelet VWF content identified in different types of VWD, focusing
on the value of measuring platelet VWF for the purpose of diagnosing VWD accurately and
understanding the mechanisms underlying this disease.
Materials and Methods
All subjects were studied after obtaining their written informed consent in accordance with the
Helsinki Declaration, and the study was approved by our institutional review board (Ethics
Committee of University of Padua and Padua Hospital; approval number 730Pt).
Hemostatic tests
Blood samples were drawn from the antecubital vein and anticoagulated using 3.8% sodium
citrate (1/10 vol/vol), which was supplemented with 60 mMN-ethylmaleimide (NEM), 50 mM
EDTA and 200 kallikrein inhibitory units (KIU)/mL of aprotinin when blood samples were
collected to assess platelet VWF content. Basic hemostatic analyses, i.e. plasma VWF antigen
(VWF:Ag), VWF collagen binding (VWF:CB), VWF ristocetin cofactor (VWF:RCo), ristoce-
tin-induced platelet aggregation (RIPA), VWF multimers and FVIII, were conducted as
described elsewhere [21]. The capacity of VWF to bind FVIII (VWF:FVIIIB) was explored
with an ELISA that uses recombinant FVIII (Baxter, Deerfield, Illinois) as exogenous FVIII
Platelet VWF and VWDDiagnosis
PLOS ONE | DOI:10.1371/journal.pone.0161310 August 17, 2016 2 / 12
[22]. DDAVP (1-desamino-8-D-arginine vasopressin; Emosint, Sclavo, Italy) was administered
subcutaneously at a dose of 0.3 μg/kg. Blood samples were collected before and then 15, 30, 60,
120, 180, 240, 360 and 480 min, and 24 hours after administering DDAVP. The time courses of
the VWF:Ag and VWF:CB plasma concentrations after DDAVP were analyzed using a one-
compartment model with first-order input and output kinetics, as described elsewhere [23].
Platelet VWF:Ag was measured with the home-made ELISA used to measure plasma VWF
[24]. Platelet-rich plasma (PRP) added with 3% EDTA in PBS buffer was centrifuged at 6800 x
g for 45 seconds. After resuspension, platelets were washed twice, then resuspended at 1 x 106/
μL in PBS-EDTA and lysed with 1% Triton-X100. A pool of platelets obtained from 20 normal
subjects, washed and adjusted to 1 x 106 /uL, was used to prepare standard curves. The values
were expressed in units per deciliter, taking the optical density in the first dilution of normal
pooled platelets as 100. The normal range for platelet VWF (70–140 U/dL) was obtained by
studying 45 normal subjects.
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA blood
Mini Kit (QIAGEN, Hilden, Germany). All 52 exons of the VWF gene, including the intron-
exon boundaries and the 3’ and 5’ regulation sites, were amplified and sequenced using primers
chosen according to the VWF sequence identified by Mancuso et al [25].
Statistical analysis
Laboratory data were expressed as means ± standard errors (SE). The t-test was used to com-
pare all the results and a correlation analysis was conducted to assess the association between
the parameters. Welch’s correction was used when variances were not equal. P values below
0.05 were considered statistically significant.
Results
The study involved 156 patients with VWD: 72 had type 1 VWD, 5 had type 3, 16 had type
Vicenza, 28 had type 2B, 14 had type 2A, and 21 had type 2N. All the type 2 VWD patients had
a phenotypic diagnosis confirmed by genetic analyses.
Type 1
Type 1 VWD was diagnosed on the strength of a homogeneous decrease in plasma VWF:Ag
and function (VWF:RCo, VWF:CB and VWF:FVIIIB) in the absence of any evident VWFmul-
timer structural abnormalities. Type 1 was divided into mild and severe forms depending on
the circulating VWF levels: cases were considered mild for VWF levels below 50 U/dL, or
severe for plasma VWF levels below 10 U/dL. Sixty-four patients had mild type 1 VWD and 8
were cases of severe type 1 VWD.
Mild type 1 VWD. Among the cases of mild type 1 VWD, 20 patients had normal platelet
VWF levels (96.4+/-4.0 U/dL [normal range 70–140 U/dL]) and 44 had a reduced platelet con-
tent (47.2+/-2.5 U/dL) (Table 1), but the multimer organization revealed no significant abnor-
malities in either instance. These patients are identified in the present paper as having normal-
platelet-VWF or low-platelet-VWF mild type 1 VWD, respectively (Fig 1). The mean plasma
VWF levels in these two groups were not dissimilar, i.e. 33.6+/-1.4 U/dL in low-platelet-VWF
cases and 37.9+/2.5 U/dL in normal-platelet-VWF patients. The low-platelet-VWF mild type 1
patients showed a significant correlation between plasma and platelet VWF content (p<0.05).
Some differences in the FVIII/VWF:Ag ratio emerged, since it appeared to be almost normal in
Platelet VWF and VWDDiagnosis
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normal-platelet-VWF mild type 1 VWD (1.3+/-0.1), but higher than normal in low-platelet-
VWF patients (1.9+/-0.2), the normal range being 0.75–1.2 (Table 1).
In the normal-platelet-VWF mild type 1 group, 8 patients belonging to 5 unrelated families
were genetically characterized, exploring the whole VWF gene: no VWF mutations were iden-
tified in 6 patients (from 3 families), while the other 2 were found heterozygous for the p.
C1130F and the new p.R670C mutations. In the low-platelet-VWF mild type 1 VWD group,
32 patients from 17 unrelated families underwent genetic investigations and VWF mutations
were identified in all but one: 71% were missense mutations (the most common being the
c.7085G>T, p.C2362F—found in 3/17 families) (Table 2), while the other 29% were null muta-
tions, i.e. nonsense nucleotide substitutions or deletions inducing a frameshift with a prema-
ture stop codon, the most common being the c.1534-3C>Amutation (in 2/17 families).
The DDAVP test was performed in 10 normal-platelet-VWF and 8 low-platelet-VWF
patients with mild type 1 VWD to examine the contribution of VWF survival in regulating
plasma VWF levels: the normal-platelet-VWF patients revealed a statistically lower VWF T1/
2elimination (T1/2el) than the low-platelet-VWF patients (5.3+/-2.0 h vs 9.1+/-4.2 h, p<0.05),
and a faster clearance (CL) (5.95+/-2.1 h vs 3.72+/-1.8 h, p<0.005) (Fig 2). The same was true
of these patients’ VWF:CB and FVIII values (Fig 2), whereas no significant difference in the
quantity (Q) of VWF and FVIII released was observed in any of the patients studied (Fig 2).
Severe type 1 VWD. The 8 patients with severe type 1 VWD all had a significantly
reduced platelet VWF content (4.8+/-1.0 U/dL), as well as significantly reduced plasma VWF
values (5.8+/-0.8 U/dL) (Fig 1). Their FVIII/VWF:Ag ratio appeared to be significantly
increased (5.2 +/-0.7) (Table 1). They were all carrying the c.1534-3G>Amutation at homozy-
gous or compound heterozygous level (Table 2) [26,27].
Type 3
All type 3 patients had platelet VWF levels below 0.10 U/dL and plasma VWF:Ag levels rang-
ing from undetectable to 0.85 U/dL, while their FVIII values were always below 10 U/dL
(Table 1). The mutations identified are listed in Table 2.
Type Vicenza
Ten families with 16 patients who had type Vicenza VWD were studied; all but one were from
north-east Italy. Their main hemostatic findings are given in Table 1. Their plasma VWF levels
were significantly reduced (10.9+/-3.69 U/dL), while platelet VWF content was normal in all
Table 1. Main haemostatic findings of the VWD patients with quantitative VWF defects studied.
VWD type No subjects/
Families
VWF:Ag
(U/dL)
VWF:CB
(U/dL)
VWF:RCo
(U/dL)
VWF:FVIIIB
(U/dL)
FVIII
(U/dL)
FVIII/VWF:
Ag
Platelet VWF
(U/dL)
BS
Mild
type 1
Normal-
platelet-VWF
20/8 37.9±11.2 35.2±13.3 35.9±11.6 33.9±10.8 47.4
±14.1
1.3±0.3 96.4±18.0 4.8
±4.1
Low-platelet-
VWF
44/32 33.6±9.2 32.0±11.2 31.8±11.0 32.2±10.5 56.8
±21.9
1.9±1.1 47.2±15.9 3.8
±3.4
Severe type 1 8/7 5.9±2.4 4.0±1.72 7.1±3.7 6.1±1.83 32.2
±17.8
5.2±1.8 4.8±2.7 11.5
±4.1
Type 3 5/3 ND ND ND ND 4.5±2.2 ND ND 24±4.8
Type Vicenza 16/10 10.7±6.2 9.4±4.8 10.6±6.9 9.6±5.3 20.3±8.9 2.0±0.8 93.8±25.1 9.7
±4.0
Normal range 60–160 65–150 60–130 65–150 60–160 0.75–1.2 70–140 0–5
ND = not detectable; BS = bleeding score from BAT (bleeding assessment tool).
doi:10.1371/journal.pone.0161310.t001
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instances (91.1+/-23.6 U/dL) (Fig 1), and the FVIII/VWF:Ag ratio appeared to be higher than
normal (2.0+/-0.2) (Table 1). Type Vicenza VWD was first diagnosed on the strength of the
low plasma VWF levels, significantly reduced VWF survival, and increased clearance (data not
shown) [28]. Type Vicenza patients carried both p.R1205H and p.M740I mutations in 14
cases, and only the p.R1205H mutation in 2 (from 2 unrelated families); the p.R1205H muta-
tion is the one that identifies type Vicenza VWD [29].
Type 2A
Type 2A VWD is characterized by an abnormal VWF-platelet interaction due to the absence of
large VWF multimers. Among the 14 patients studied, 9 were type 2A-I (with an abnormal
VWF synthesis and multimerization), and 5 were type 2A-II (carrying mutations that make
VWF more susceptible to proteolysis by ADAMTS13). Type 2A-I was characterized by lower
Fig 1. Mean plasma and platelet VWF in patients with quantitative (upper panel) and functional (lower
panel) VWF defects. Type 1 VWD patients were divided into severe and mild cases, based on their
circulating VWF levels (< 10U/dL and < 50 U/dL, respectively). Mild type 1 patients were further grouped
according to their normal or low platelet VWF content. Functional VWF defects in type 2A were separated into
a defective VWF synthesis (2A-I) and an increased susceptibility to ADAMTS13 (2A-II). Type 2B cases were
divided according to their multimer pattern, and type 2N according to whether VWF synthesis was normal or
reduced, the latter depending on the nature of the type 2N mutation, or the presence of a combined
quantitative VWFmutation.
doi:10.1371/journal.pone.0161310.g001
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plasma VWF:Ag (23.3+/-2.9 U/dL) and platelet (52.6+/-7.3 U/dL) levels, with a more pro-
nounced reduction in VWF:CB and VWF:RCo (13.7+/-2.1 U/dL and 9.9+/-1.1 U/dL, respec-
tively). The FVIII/VWF:Ag ratio was slightly increased (1.8+/-0.2) (Table 3). In type 2A-II,
platelet VWF:Ag was normal (mean 80.7+/- 5.1 U/dL), while VWF:Ag was reduced (42.8
+/-4.7), and VWF:CB and VWF:RCo were even more so (4.4+/-3.1 U/dL and 19.0+/-2.6 U/dL,
respectively) (Table 3), but the FVIII/VWF:Ag ratio was almost normal (Fig 2). The mutations
involved in types 2A-I and 2A-II are listed in Table 2.
Type 2B
Type 2B VWD patients were characterized by platelet hyper-responsiveness to ristocetin in the
presence of mutations in the VWF A1 domain. Eight patients had no large VWF multimers,
while 10 had a full complement of VWF oligomers. Type 2B patients with abnormal VWFmul-
timers had a lower VWF:Ag (41.7+/-3.9 U/dL), and a more pronounced reduction in VWF:CB
(8.3+/-0.9 U/dL) and VWF:RCo (16.9+/-2.2U/dL) (Table 3), whatever the mutations they car-
ried (Table 2). Platelet VWF content was normal (118.1+/-10.3 U/dL) in patients with both
normal and reduced platelet counts, however. Type 2B patients with a normal multimer pat-
tern had a more complex hemostatic profile, characterized by a concordant reduction in VWF:
Ag, VWF:CB and VWF:RCo (Table 3), coinciding with the presence of all VWF multimers.
Platelet VWF levels proved more heterogeneous: they were reduced in patients carrying the p.
R1379C and p.R1341Wmutations (mean 52.36+/-8.9 U/dL), and normal in patients carrying
the p.I1372S substitution (mean 115.8+/-20.8 U/dL) [30]. The FVIII/VWF:Ag ratio of type 2B
Table 2. Genetic mutations in the VWD patients studied.
VWD type Missense Non sense Splicing Deletion/Insertion Compound
Mild type
1
Normal-platelet-
VWF
p.R670Cp.C1130F - - - -
Low-platelet-
VWF
p.Y1584Cp.
L1733Pp.P2063Sp.
C2362Fp.G2705R
p.C921*p.
E2539*
p.
L512Pfs*11
p.P812Rfs*31p.
Q104Rfs*19p.
L757Vfs*22
p.C2627Y; p.C388Wp.C524Y; p.M740I; p.
R924Qp.V1279I; p.Q1311*
Severe
type 1
- - - - p.L512Pfs*11; p.H2378Afs*?p.L512Pfs*11; p.
L512Pfs*11p.L512Pfs*11; p.C584Fp.
L512Pfs*11; p.Q706*p.L512Pfs*11; p.C2362Fp.
L512Pfs*11; p.H2378Afs; p.R2535*
Type 3 - - - - p.S1338*; p.S1338*p.E244Lfs*211; p.
E244Lfs*211p.E244Lfs*211; p.C584F
Type
Vicenza
p.R1205H - - - p.M740I; p.R1205H
Type 2A I p.L1446Pp.
R1597W
- - - p.A542G; p.R1374H
II p.L1562Pp.
I1628Tp.G1609R
- - - -
Type 2B Abnormal
multimers
p.R1308Cp.
R1306Wp.V1316M
- - - -
Normal multimers p.I1372Sp.
R1379Cp.R1341W
- - - p.P1266Q; p.R1379C
Type 2N Normal VWF
synthesis
p.R854Qp.R760C - - - p.R760C; p.R854Qp.R854Q; p.R854Q
Compound
orreduced VWF
synthesis
- - - p.R854Q; p.G2352_C2360delp.R854Q; p.
P812Rfs*31
All mutations are named according to the HGVS (Human Genome Variation Society) recommendations.
doi:10.1371/journal.pone.0161310.t002
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patients with normal multimers was similar to that of normal individuals or patients with type
2B VWD and an abnormal multimer pattern (Table 3). So, while VWF synthesis was normal
in patients with an abnormal multimer pattern (consistently with their normal platelet VWF
content), type 2B patients with normal multimers usually (though not always) had an impaired
VWF synthesis.
Type 2N
This type of VWD was diagnosed on the grounds of a defective capacity of VWF to bind FVIII,
as explored by means of the VWF:FVIIIB test. Among the 21 patients studied, 18 were homo-
zygous or heterozygous for the p.R854Q VWFmutation, 1 was carrying the p.R760C mutation,
Fig 2. Mean post-DDAVP pharmacokinetic parameters of VWF:Ag, VWF:CB and FVIII in patients with
normal-platelet-VWF and low-platelet-VWFmild type 1 VWD. The VWF T1/2elimination (T1/2el) was
statistically shorter, and VWF clearance (Cl) was significantly faster in the former patients than in the latter.
doi:10.1371/journal.pone.0161310.g002
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which induces a persistence of the VWF propeptide that interferes with FVIII binding, 1 was
compound heterozygous for the p.R854Q and p.R760C mutations, and 1 was compound het-
erozygous for the p.R854Q and p.G2352_C2360del mutations. All patients carrying the p.
R854Q alone had normal platelet and plasma VWF levels, but if there was a p.R760C mutation,
alone or in combination with a p.R854Q mutation, then plasma VWF was reduced (and
platelet VWF was not) in the presence of a defective VWF:FVIIIB (Table 3). On the other
hand, patients carrying the p.R854Q mutation combined with the p.P812Rfs31 and p.
G2352_C2360del mutations had low levels of both plasma and platelet VWF (Table 3). No sig-
nificant differences in the FVIII/VWF:Ag ratio emerged between the two groups of patients
(Table 3).
Discussion
The characterization and typing of VWD is a complicated matter and numerous tests are
needed to arrive at a precise diagnosis. This study shows that measuring platelet VWF can be
helpful in characterizing VWD by revealing when VWF synthesis is impaired.
The VWF abnormalities underlying inherited VWDmay concern the synthesis or the func-
tioning of VWF, or combinations of these factors. VWF synthesis is assessed mainly by mea-
suring plasma VWF concentrations, which are the result of the constitutive release of the VWF
synthesized in endothelial cells. A reduction in plasma VWF can therefore be interpreted as an
expression of its reduced synthesis. Plasma VWF may also be down-regulated due to a shorter
VWF survival, however, as seen in type Vicenza VWD, which is characterized by a VWF that
is synthesized and stored normally, but subject to an increased clearance [28], and this makes it
difficult to interpret the significance of low circulating VWF levels. The DDAVP test also can
be used to shed light on VWF synthesis because it induces an acute release of the VWF stored
in the Weibel Palade bodies of endothelial cells: since a reduced VWF synthesis will give rise
to its reduced storage, the post-DDAVP normalization of plasma VWF may be impaired as a
result.
Table 3. Main haemostatic findings of the VWD patients studied characterized by VWF functional abnormalities.
VWD
type
Subtype No subjects/
families
VWF:Ag
(U/dL)
VWF:CB
(U/dL)
VWF:
RCo
(U/dL)
VWF:
FVIIIB
(U/dL)
FVIII
(U/dL)
FVIII/
VWF:Ag
Platelet
VWF(U/dL)
RIPA
(%)
MADR
(mg/mL)
BS
Type 2A I 9/3 23.3
±8.6
13.7
±6.2
9.9±3.3 17.8±8.7 37.7
±10.8
1.8±0.5 52.6±20.6 6.9
±3.4
- 10.5
±3.7
II 5/4 42.8
±10.4
4.4±5.4 19.0±5.1 46.2±5.7 53.3
±6.9
1.3±0.3 80.7±11.5 0 - 5.0
±2.6
Type 2B Abnormal
multimers
18/9 41.7
±16.7
8.3±3.8 16.9±9.2 - 49.4
±11.8
1.3±0.4 118.1±42.3 69.5
±14.6
0.4±0.1 11.8
±4.4
Normal multimers 10/5 75.2
±52.4
75.5
±54.8
60.5
±47.1
- 74.4
±38.6
1.2±0.4 71.9±24.4 78.6
±6.8
0.6±0.1 9.7
±4.7
Type 2N Normal VWF
synthesis
18/11 106
±56.2
88.5
±35.9
96.2
±41.6
59.2±37.2 68.4
±28.3
0.7±0.3 122.1±53.0 74.8
±21.1
- 3.6
±3.0
Compound or
reduced VWF
synthesis
3/2 45.4
±3.9
46.0
±1.6
46.3±4.1 11.6±3.4 29.2
±8.1
0.6±0.2 30.4±23.5 72.4
±6.8
- 13
±3.8
Normal
values
60–160 65–150 60–130 65–150 60–160 0.75–
1.2
70–140 58–82 1.0mg/
mL
0–5
BS = bleeding score from BAT (bleeding assessment tool); RIPA = Ristocetin-induced platelet aggregation at 1.2 mg/mL ristocetin concentration;
MADR = minimal aggregating dose ristocetin.
doi:10.1371/journal.pone.0161310.t003
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Platelet VWF is synthesized in megakaryocytes and stored in platelet alpha granules by
means of processes that are apparently not dissimilar to those involved in endothelial cells.
This means that measuring platelet VWF provides information on the processes occurring in
endothelial cells. Platelet VWF is rarely measured, but it is a good tool for exploring VWF syn-
thesis because—unlike plasma VWF—it is uninfluenced by environmental factors, especially
aging and morbidities; in our experience, platelet VWF does not change significantly with age,
whereas circulating VWF does, especially in type 1 VWD patients with mild VWF defects
(unpublished data).
In the present study, platelet and plasma VWF levels were almost undetectable in patients
with type 3 VWD, confirming that VWF synthesis is negligible or totally lacking in these
patients. The picture of type 1 VWD is more complex. Most—but not all—patients with this
form showed a correlation between platelet and plasma VWF; this was always true for patients
with severe type 1 VWD, but not in those with mild type 1 VWD, some of whom had a normal
platelet VWF content, while it was reduced in the others. The two groups of patients identified
in this paper as having normal-platelet-VWF and low-platelet-VWF mild type 1 VWD had no
statistically significant differences in their circulating VWF levels. The patients with a normal
platelet VWF content included both single cases and familial clusters, which confirms that
their hemostatic picture is genetically determined. These patients’ bleeding scores were normal
or slightly increased (with no significant differences between the two sub-groups). The differ-
ence in platelet VWF content therefore does not seem to significantly affect a patient’s ten-
dency to bleed.
All but one of the genetically investigated low-platelet-VWF mild type 1 patients carried
VWF mutations, whereas only 2 of the 8 normal-platelet-VWF mild type 1 patients revealed
VWF mutations (p.C1130F and p.R670C). This raises the question of why plasma VWF is
reduced in these patients despite their normal VWF synthesis. An answer comes from the
DDAVP test, which showed that VWF survival and clearance were respectively lower and
higher in mild type 1 VWD patients with normal platelet VWF than in those with low platelet
VWF. It is easy to explain why this happens in the patient carrying the p.C1130F mutation
(known to be associated with a shorter VWF half-life) [31], but not in the others—especially
those who apparently have no mutations in the coding portion of their VWF gene. It might be
tentatively advanced that these patients have unknown factors outside the VWF molecule that
regulate VWF clearance. In addition, measuring platelet VWF also seems useful for predicting
response to DDAVP when it has to be used for therapeutic purposes. It has been clearly dem-
onstrated by different groups that type 1 VWD patients with low platelet VWF levels [32]
respond to DDAVP less well than patients with a normal platelet VWF content [16, 33].
Type Vicenza is probably one of forms of VWD in which measuring platelet VWF is partic-
ularly useful. Circulating VWF levels are reduced in these patients, with values sometimes
below 10 U/dL (as in severe type 1 VWD), while their platelet VWF content is normal. At our
laboratory, these two divergent features are considered the hallmark of type Vicenza patients
because, to the best of our knowledge, no other forms of VWD feature this marked discrep-
ancy; this finding consequently prompts a search for the type Vicenza mutation (p.R1205H)
[29].
Measuring platelet VWF is similarly useful in type 2A VWD, which is characterized by an
abnormal platelet-VWF interaction due to a shortage of large VWF multimers. Two subtypes
of type 2A VWD have been described: type 2A-I with a low platelet VWF content, and type
2A-II with a normal platelet VWF content [34]. It may be difficult to distinguish between the
two forms, and measuring platelet VWF can be very helpful in this setting. Drawing this dis-
tinction is by no means irrelevant because patients with type 2A-I VWD generally have a
more pronounced bleeding tendency than those with type 2A-II, as demonstrated by their BS.
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Two main pictures can be seen in type 2B VWD as well, i.e. patients lacking in circulating
large VWF multimers and those with a normal multimer pattern. In both cases, their VWF has
a greater affinity for platelet GPIb. Platelet VWF levels are normal in the former, and often
(but not always) lower than normal in the latter. Measuring platelet content is probably less
useful in this setting than in the previously-mentioned types of VWD because in type 2B VWD
it is important to ascertain the greater affinity of VWF for platelets and check for the presence
or absence of large VWF multimers. Establishing patients’ platelet VWF levels is still useful,
however, for characterizing the VWD phenotype.
Platelet VWF is always normal in type 2N VWD, unless patients simultaneously carry a sec-
ond mutation that impairs VWF synthesis, such as the p.P812Rfs31 and p.G2352_C2360del
mutations found in our cohort. This means that measuring platelet VWF in cases of type 2N
VWD can help to establish whether any other mutations are involved, particularly considering
that recessive quantitative defects may not be very obvious if only plasma VWF is measured (as
discussed above). This applies to other forms of VWD too, when the phenotype does not neatly
fit the canonical criteria.
Other tools are currently used to identify a defective VWF synthesis, the most commonly
adopted being the FVIII/VWF:Ag ratio [35,36]: a higher ratio is suggestive of a reduction in
VWF synthesis, while a normal ratio points to VWF alterations being attributable to a shorter
VWF survival. This distinction seems to apply in our patients too—with the exception of type
Vicenza VWD patients, whose FVIII/VWF:Ag ratio increases despite their main defect being
associated with a marked reduction in VWF survival. For other forms of type 1 VWD, a corre-
lation is apparent between a rising FVIII/VWF:Ag ratio and falling platelet VWF levels, since
patients with severe type 1 VWD had the most pronounced increase in their FVIII/VWF:Ag
ratio, while it was nearly normal in patients with normal-platelet-VWF mild type 1 VWD. The
same applies to VWD types 2A and 2B, though the increase in the FVIII/VWF:Ag ratio in the
forms associated with a defective VWF synthesis is negligible, and consequently less informa-
tive. Combining the FVIII/VWF:Ag ratio with platelet VWF levels could therefore facilitate the
demonstration of a defective VWF synthesis.
In conclusion, measuring platelet VWF is an excellent way to study VWD for several rea-
sons: it enables a distinction to be drawn between quantitative and qualitative VWF defects; it
helps to identify the affected members in the families of patients with type 1 VWD, especially
when their plasma VWF levels are not informative; it distinguishes between cases of mild type
1 VWD with normal as opposed to low platelet VWF levels; it grades the severity of a defective
VWF synthesis; it identifies cases of type Vicenza VWD; it distinguishes type 2A-I from type
2A-II disease; it better characterizes type 2B VWD; it identifies type 2N patients who carry
quantitative VWF mutations too; it predicts which patients will respond to DDAVP, and also
the bleeding risk of VWD patients, especially for those carrying a quantitative VWF defect.
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